Department of Urology, Weill Cornell Medicine, New York City, NY, USA.
Department of Urology, Northwell Health, Manhasset, NY, USA.
Curr Urol Rep. 2024 Oct 7;26(1):9. doi: 10.1007/s11934-024-01235-3.
The prevalence of benign prostatic hyperplasia (BPH) is rising, however, current treatment options present severe complications and limit patient's quality of life. Accordingly, advancements in prostatic catheter and stent designs for use in treating lower urinary tract symptoms (LUTS) in BPH patients have largely expanded in the past five years and we aim to provide an exhaustive summary of recent outcomes.
The dual dilation and paxlitaxel eluting Optilume BPH Catheter System enhances promise in catheter-based treatments, providing the longest sustained increase in max urinary flow rate and decrease in post-void residual volume compared to alternative MISTs. Additionally, use of iTiND, along with recent advancements in temporary (EXIME, Prodeon Urocross) and permanent (Zenflow Spring, Butterfly, and ClearRing) stent designs, have demonstrated rapid, lasting, and low-cost LUTS relief with sustained sexual function. Minimally invasive solutions that offer in-office treatment, rapid symptom relief, shorter recovery times, and preservation of sexual function hold great promise in improving outcomes in managing BPH patients with LUTS.
良性前列腺增生（BPH）的发病率正在上升，然而，目前的治疗选择存在严重的并发症，并限制了患者的生活质量。因此，在过去五年中，用于治疗 BPH 患者下尿路症状（LUTS）的前列腺导管和支架设计的进步有了很大的扩展，我们旨在提供对近期结果的详尽总结。
双扩张和紫杉醇洗脱 Optilume BPH 导管系统在基于导管的治疗中具有更大的潜力，与其他 MIST 相比，提供了最长的持续最大尿流率增加和残余尿量减少。此外，iTiND 的使用以及临时（EXIME、Prodeon Urocross）和永久（Zenflow Spring、Butterfly 和 ClearRing）支架设计的最新进展，已经证明了快速、持久和低成本的 LUTS 缓解，同时保持了性功能。提供门诊治疗、快速症状缓解、更短的恢复时间和保留性功能的微创解决方案，有望改善管理 LUTS 的 BPH 患者的治疗结果。
